A long-awaited moment for consumers arrived last year when patent protection expired on the nation’s most prescribed medicine, AbbVie’s wildly successful — and costly — rheumatoid arthritis drug ...

This week CVS Health launched Cordavis, a wholly owned subsidiary that will work with manufacturers to commercialize and/or co-produce biosimilar products for the U.S. pharmaceutical market. The ...

Blue Shield of California is shaking up the pharmacy landscape with a landmark deal to drastically reduce the price of a biosimilar alternative to AbbVie Inc.’s (NYSE:ABBV) Humira, one of the world’s ...

Blue Shield of California will purchase Idacio at $525 per dose, significantly cheaper than Humira's $2100 price, enhancing affordability for patients. Collaboration with Fresenius Kabi and Evio ...

Tennessee last year spent $48 million on a single drug, Humira—about $62,000 for each of the 775 patients who were covered by its employee health insurance program and receiving the treatment. So when ...

Forbes contributors publish independent expert analyses and insights. Joshua Cohen is a Boston-based writer who covers health policy. Blue Shield of California is bypassing traditional pharmacy ...

This year, CVS Health plans to employ the classic "out with the old, in with the new" mantra when it comes to AbbVie’s Humira. Come April 1, the branded drug will be replaced by cheaper biosimilars ...

The biosimilar price is about 85% lower than that of branded Humira. More than 100,000 Accredo patients use either Humira or one of its biosimilars. 9 Out of the Last 10 Summers this "Power Pattern" ...

Humira's continued dominance after losing patent protection is one example of why the system for distributing drugs is broken. More than 300,000 Americans use a medication called Humira. Most of them ...